2019
DOI: 10.1074/jbc.ra118.004731
|View full text |Cite
|
Sign up to set email alerts
|

Nature-inspired design and evolution of anti-amyloid antibodies

Abstract: 3 The abbreviations used are: A␤, amyloid ␤; CDR, complementarity-determining region; scFv, single-chain variable fragment; V H , variable domain of heavy-chain; Fc, fragment crystallizable; HCDR3, heavy chain CDR3; BisTris, 2-[bis(2-hydroxyethyl)amino]-2-(hydroxymethyl)propane-1,3-diol; IAPP, islet amyloid polypeptide; RCF, relative centrifugal force; APP, amyloid precursor protein; HFIP, hexafluoro-2-propanol; Ni-NTA, nickel-nitrilotriacetic acid; DMEM, Dulbecco's modified Eagle's medium; KLH, keyhole limpet… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
4
1

Citation Types

2
26
0

Year Published

2019
2019
2024
2024

Publication Types

Select...
3
2

Relationship

2
3

Authors

Journals

citations
Cited by 25 publications
(28 citation statements)
references
References 57 publications
2
26
0
Order By: Relevance
“…The conformational antibodies reported in this study against liraglutide fibrils and related conformational antibodies against glucagon fibrils (Stimple et al, 2019), which were produced using similar directed evolution methods, possess several unique molecular features relative to other conformational and conventional antibodies. First, the heavy chain CDR3s of our liraglutide and glucagon antibodies have unusually large numbers of aromatic amino acids (10.3 ± 1.4 Trp, Phe, and Tyr residues) relative to Aβ conformational (2.9 ± 1.9 aromatic residues) and nonconformational (2.6 ± 2.1 aromatic residues) antibodies (for a summary of these antibodies, see Julian et al, 2019) as well as human antibodies in general (3.3 ± 1.7 aromatic residues). Second, our liraglutide and glucagon conformational antibodies have heavy chain CDR3s that are much more negatively charged (−5.8 ± 0.4 net charge at pH 7.4) than those of Aβ conformational (−0.3 ± 1.6) and nonconformational (−1.4 ± 1.5) antibodies as well as human antibodies in general (−1.4 ± 1.3).…”
Section: Discussionmentioning
confidence: 99%
See 2 more Smart Citations
“…The conformational antibodies reported in this study against liraglutide fibrils and related conformational antibodies against glucagon fibrils (Stimple et al, 2019), which were produced using similar directed evolution methods, possess several unique molecular features relative to other conformational and conventional antibodies. First, the heavy chain CDR3s of our liraglutide and glucagon antibodies have unusually large numbers of aromatic amino acids (10.3 ± 1.4 Trp, Phe, and Tyr residues) relative to Aβ conformational (2.9 ± 1.9 aromatic residues) and nonconformational (2.6 ± 2.1 aromatic residues) antibodies (for a summary of these antibodies, see Julian et al, 2019) as well as human antibodies in general (3.3 ± 1.7 aromatic residues). Second, our liraglutide and glucagon conformational antibodies have heavy chain CDR3s that are much more negatively charged (−5.8 ± 0.4 net charge at pH 7.4) than those of Aβ conformational (−0.3 ± 1.6) and nonconformational (−1.4 ± 1.5) antibodies as well as human antibodies in general (−1.4 ± 1.3).…”
Section: Discussionmentioning
confidence: 99%
“…The antibodies were isolated through two stages of library sorting. In the first stage of sorting, a single‐chain variable fragment (scFv) library was generated by diversification of heavy chain CDR3 (HCDR3) of the 4D5 scFv (Julian et al, 2019; Stimple et al, 2019; Tiller et al, 2017). To avoid concerns related to selection bias towards positively charged residues (Rabia et al, 2018), the library was diversified at 15 sites in HCDR3, at a frequency of 2–6 amino acids per site, while omitting positively charged residues (and cysteine) from the library.…”
Section: Methodsmentioning
confidence: 99%
See 1 more Smart Citation
“…Antibodies (scFvs) specific for glucagon fibrils were isolated using mutagenesis (Tiller, Chowdhury et al, ), yeast surface display and magnetic sorting using Dynabeads (Dynabeads M‐280 Tosylactivated, 14203; Invitrogen, Carlsbad, CA) coated with immobilized fibrillar or soluble glucagon using methods related to those reported previously (Julian et al, ). Briefly, 8 × 10 7 beads were washed twice with 1 ml of PBS.…”
Section: Methodsmentioning
confidence: 99%
“…The antibodies were expressed transiently in adherent HEK 293T cells (CRL‐3216; ATCC, Manassas, VA) using Invitrogen Lipofectamine 2000 Transfection Reagent (11668019; Thermo Fisher Scientific), as described previously (Julian et al, ; Rabia, Zhang, Ludwig, Julian, & Tessier, ; Tiller, Li et al, ). Briefly, cells were cultured in ~15 ml of Dulbecco's Modified Eagle's Medium (DMEM) culture media (10569‐044; Thermo Fisher Scientific) supplemented with 10% fetal bovine serum (35010CV; Corning, Corning, NY) and 1% penicillin/streptomycin (15140122; Thermo Fisher Scientific) in 75 cm 2 cell culture flasks (0030711122; Eppendorf, Hamburg, Germany) until reaching ~80% confluence.…”
Section: Methodsmentioning
confidence: 99%